Strategic Intelligence Report
Generated July 29, 2026
AI Labs
Tempus AI
Strategic importance is our editorial rating of how central this entity is to the technology landscape we track; confidence reflects how well-sourced and current the underlying evidence is.
0
Chokepoint Score
no direct dependencies recorded in the graph
Steady
Momentum
insider filing activity unchanged since last check
Headquarters
Chicago, Illinois, USA
Website
Employees
2,600 (2025, approximate)
Founded
2015
Listing
TEM · NASDAQ
Market Cap
$7.73B
Revenue (TTM)
$1.36B
Price
USD42.91 (-11.36%)
Market data as of Jul 28, 2026, 11:21 AM · Source: Yahoo Finance (delayed). Not investment advice.
Overview
A precision medicine company applying AI to genomic sequencing and clinical data, combining diagnostics and data-licensing businesses to accelerate oncology treatment decisions and drug development. Tempus AI reported Q1 2026 revenue of $348.1 million (up 36.1% year-over-year), with Diagnostics revenue of $261.1 million (driven by 28% oncology volume growth); minimal residual disease test volume reached approximately 6,500 tests in Q1 2026, up roughly 500% year-over-year.
Dependency Map
One hop in each direction — see Strategic Connections below for the full, sourced breakdown of every relationship.
Strategic Connections
Dependency
- Amazon Web Services: Tempus AI relies predominantly on Amazon Web Services for cloud infrastructure, using AWS for the majority of its data storage and processing needs alongside a smaller Google Cloud commitment.
Competition / Other
- Healthcare & Life Sciences: Tempus AI operates within the healthcare and life sciences industry, applying AI to genomic sequencing, diagnostics, and precision oncology.
Strategic Risks
- Healthcare data and diagnostics business faces regulatory and reimbursement complexity
Future Outlook
- Continued growth in oncology diagnostics volume and data-licensing revenue toward sustained profitability
Sources
- U.S. Securities and Exchange Commission (EDGAR) (Feb 2026) — Tempus AI FY2025 Annual Report (Form 10-K), filed with the SEC
- Tempus AI Q1 2026 earnings release (May 2026) — Tempus AI Q1 2026 revenue up 36% to $348M, raises full-year guidance to $1.6B
- Tempus AI Q1 2026 earnings coverage (Tickeron) (May 2026) — Tempus AI's MRD cancer-monitoring test volume surges roughly 500% year-over-year in Q1 2026
Generated by InsightNodes — Technology Intelligence Platform. This report reflects sourced, evidence-backed information as of the dates cited above and is not investment advice.
Viewing the Full Analyst Report — switch to the Executive Summary.